CIPHER PHARMACEUTICALS INC (CPH.CA) Stock Fundamental Analysis
TSX:CPH - Toronto Stock Exchange - CA17253X1050 - Common Stock - Currency: CAD
CPH gets a fundamental rating of 6 out of 10. The analysis compared the fundamentals against 34 industry peers in the Pharmaceuticals industry. CPH scores excellent on profitability, but there are some minor concerns on its financial health. CPH is growing strongly while it is still valued neutral. This is a good combination! These ratings could make CPH a good candidate for growth investing.
1. Profitability
1.1 Basic Checks
CPH had positive earnings in the past year.
CPH had a positive operating cash flow in the past year.
CPH had positive earnings in each of the past 5 years.
Each year in the past 5 years CPH had a positive operating cash flow.
1.2 Ratios
The Return On Assets of CPH (5.67%) is better than 91.18% of its industry peers.
With an excellent Return On Equity value of 8.79%, CPH belongs to the best of the industry, outperforming 88.24% of the companies in the same industry.
Looking at the Return On Invested Capital, with a value of 3.60%, CPH is in the better half of the industry, outperforming 76.47% of the companies in the same industry.
Measured over the past 3 years, the Average Return On Invested Capital for CPH is in line with the industry average of 8.08%.
The last Return On Invested Capital (3.60%) for CPH is well below the 3 year average (8.42%), which needs to be investigated, but indicates that CPH had better years and this may not be a problem.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 5.67% | ||
| ROE | 8.79% | ||
| ROIC | 3.6% |
ROA(3y)22.3%
ROA(5y)18.43%
ROE(3y)26.05%
ROE(5y)22.41%
ROIC(3y)8.42%
ROIC(5y)14.92%
1.3 Margins
The Profit Margin of CPH (23.40%) is better than 97.06% of its industry peers.
In the last couple of years the Profit Margin of CPH has grown nicely.
Looking at the Operating Margin, with a value of 18.39%, CPH belongs to the top of the industry, outperforming 88.24% of the companies in the same industry.
CPH's Operating Margin has declined in the last couple of years.
Looking at the Gross Margin, with a value of 71.95%, CPH belongs to the top of the industry, outperforming 94.12% of the companies in the same industry.
In the last couple of years the Gross Margin of CPH has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 18.39% | ||
| PM (TTM) | 23.4% | ||
| GM | 71.95% |
OM growth 3Y-26.62%
OM growth 5Y-14.41%
PM growth 3Y-0.73%
PM growth 5Y19.11%
GM growth 3Y-4.61%
GM growth 5Y-3.67%
2. Health
2.1 Basic Checks
CPH has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
Compared to 1 year ago, CPH has more shares outstanding
CPH has less shares outstanding than it did 5 years ago.
The debt/assets ratio for CPH is higher compared to a year ago.
2.2 Solvency
An Altman-Z score of 3.73 indicates that CPH is not in any danger for bankruptcy at the moment.
With an excellent Altman-Z score value of 3.73, CPH belongs to the best of the industry, outperforming 94.12% of the companies in the same industry.
A Debt/Equity ratio of 0.38 indicates that CPH is not too dependend on debt financing.
CPH has a Debt to Equity ratio (0.38) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.38 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 3.73 |
ROIC/WACC0.42
WACC8.62%
2.3 Liquidity
A Current Ratio of 2.28 indicates that CPH has no problem at all paying its short term obligations.
With a Current ratio value of 2.28, CPH perfoms like the industry average, outperforming 58.82% of the companies in the same industry.
A Quick Ratio of 1.97 indicates that CPH should not have too much problems paying its short term obligations.
CPH's Quick ratio of 1.97 is fine compared to the rest of the industry. CPH outperforms 73.53% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.28 | ||
| Quick Ratio | 1.97 |
3. Growth
3.1 Past
CPH shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -59.55%.
Measured over the past years, CPH shows a quite strong growth in Earnings Per Share. The EPS has been growing by 12.47% on average per year.
CPH shows a strong growth in Revenue. In the last year, the Revenue has grown by 78.42%.
CPH shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 8.25% yearly.
EPS 1Y (TTM)-59.55%
EPS 3Y13.23%
EPS 5Y12.47%
EPS Q2Q%-50%
Revenue 1Y (TTM)78.42%
Revenue growth 3Y14.99%
Revenue growth 5Y8.25%
Sales Q2Q%104.86%
3.2 Future
Based on estimates for the next years, CPH will show a quite strong growth in Earnings Per Share. The EPS will grow by 16.25% on average per year.
Based on estimates for the next years, CPH will show a very strong growth in Revenue. The Revenue will grow by 21.22% on average per year.
EPS Next Y40.28%
EPS Next 2Y27.42%
EPS Next 3Y16.25%
EPS Next 5YN/A
Revenue Next Year56.92%
Revenue Next 2Y30.52%
Revenue Next 3Y21.22%
Revenue Next 5YN/A
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
CPH is valuated quite expensively with a Price/Earnings ratio of 26.06.
Based on the Price/Earnings ratio, CPH is valued a bit cheaper than 79.41% of the companies in the same industry.
Compared to an average S&P500 Price/Earnings ratio of 27.15, CPH is valued at the same level.
With a Price/Forward Earnings ratio of 12.80, CPH is valued correctly.
Compared to the rest of the industry, the Price/Forward Earnings ratio of CPH indicates a rather cheap valuation: CPH is cheaper than 91.18% of the companies listed in the same industry.
When comparing the Price/Forward Earnings ratio of CPH to the average of the S&P500 Index (21.60), we can say CPH is valued slightly cheaper.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 26.06 | ||
| Fwd PE | 12.8 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of CPH indicates a somewhat cheap valuation: CPH is cheaper than 61.76% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 20.14 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
CPH has an outstanding profitability rating, which may justify a higher PE ratio.
A more expensive valuation may be justified as CPH's earnings are expected to grow with 16.25% in the coming years.
PEG (NY)0.65
PEG (5Y)2.09
EPS Next 2Y27.42%
EPS Next 3Y16.25%
5. Dividend
5.1 Amount
No dividends for CPH!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
TSX:CPH (6/27/2025, 7:00:00 PM)
12.77
-0.09 (-0.7%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners1.35%
Inst Owner ChangeN/A
Ins Owners4.67%
Ins Owner ChangeN/A
Market Cap327.17M
Analysts77.78
Price Target16.34 (27.96%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-22.2%
Min EPS beat(2)-37.21%
Max EPS beat(2)-7.18%
EPS beat(4)1
Avg EPS beat(4)-34.34%
Min EPS beat(4)-94.79%
Max EPS beat(4)1.84%
EPS beat(8)5
Avg EPS beat(8)60.91%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-0.6%
Min Revenue beat(2)-0.68%
Max Revenue beat(2)-0.52%
Revenue beat(4)1
Avg Revenue beat(4)0.73%
Min Revenue beat(4)-2.71%
Max Revenue beat(4)6.82%
Revenue beat(8)3
Avg Revenue beat(8)7.2%
Revenue beat(12)3
Avg Revenue beat(12)0.33%
Revenue beat(16)4
Avg Revenue beat(16)-1.04%
PT rev (1m)-4.19%
PT rev (3m)-14.67%
EPS NQ rev (1m)0%
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)-1.32%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.74%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 26.06 | ||
| Fwd PE | 12.8 | ||
| P/S | 6.07 | ||
| P/FCF | N/A | ||
| P/OCF | 11.24 | ||
| P/B | 2.28 | ||
| P/tB | 22.23 | ||
| EV/EBITDA | 20.14 |
EPS(TTM)0.49
EY3.84%
EPS(NY)1
Fwd EY7.81%
FCF(TTM)-3.13
FCFYN/A
OCF(TTM)1.14
OCFY8.9%
SpS2.11
BVpS5.61
TBVpS0.57
PEG (NY)0.65
PEG (5Y)2.09
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 5.67% | ||
| ROE | 8.79% | ||
| ROCE | 4.99% | ||
| ROIC | 3.6% | ||
| ROICexc | 4.24% | ||
| ROICexgc | 18.03% | ||
| OM | 18.39% | ||
| PM (TTM) | 23.4% | ||
| GM | 71.95% | ||
| FCFM | N/A |
ROA(3y)22.3%
ROA(5y)18.43%
ROE(3y)26.05%
ROE(5y)22.41%
ROIC(3y)8.42%
ROIC(5y)14.92%
ROICexc(3y)14.84%
ROICexc(5y)25.78%
ROICexgc(3y)32.35%
ROICexgc(5y)N/A
ROCE(3y)11.69%
ROCE(5y)20.72%
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3Y-55.02%
ROICexc growth 5Y-33.6%
OM growth 3Y-26.62%
OM growth 5Y-14.41%
PM growth 3Y-0.73%
PM growth 5Y19.11%
GM growth 3Y-4.61%
GM growth 5Y-3.67%
F-Score4
Asset Turnover0.24
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.38 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 3.14 | ||
| Cap/Depr | 1442.16% | ||
| Cap/Sales | 202.56% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 166.44% | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.28 | ||
| Quick Ratio | 1.97 | ||
| Altman-Z | 3.73 |
F-Score4
WACC8.62%
ROIC/WACC0.42
Cap/Depr(3y)670.82%
Cap/Depr(5y)415.05%
Cap/Sales(3y)80.33%
Cap/Sales(5y)48.9%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-59.55%
EPS 3Y13.23%
EPS 5Y12.47%
EPS Q2Q%-50%
EPS Next Y40.28%
EPS Next 2Y27.42%
EPS Next 3Y16.25%
EPS Next 5YN/A
Revenue 1Y (TTM)78.42%
Revenue growth 3Y14.99%
Revenue growth 5Y8.25%
Sales Q2Q%104.86%
Revenue Next Year56.92%
Revenue Next 2Y30.52%
Revenue Next 3Y21.22%
Revenue Next 5YN/A
EBIT growth 1Y-32.36%
EBIT growth 3Y-15.61%
EBIT growth 5Y-7.36%
EBIT Next Year136.78%
EBIT Next 3Y39.87%
EBIT Next 5YN/A
FCF growth 1Y-549.18%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y62.22%
OCF growth 3Y12.28%
OCF growth 5Y19.77%